{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-037414","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.067251+00:00","generated_at":"2026-05-16T13:38:44.816214+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin Biotech raises ~$6.8M via warrant exercise inducement, issues new Series G warrants","bullets":["Entered inducement letters with holders of Series C/D/F warrants to exercise at $6.63 or $6.3219 per share.","Company expects aggregate gross proceeds of up to ~$6.8M from the warrant exercises.","In exchange, issues new Series G warrants to purchase up to 2,610,823 shares (250% of exercised shares) at $6.63, exercisable upon shareholder approval, 5-year term.","New warrants include anti-dilution price reset with a floor of $1.326 per share and cashless exercise feature.","Company to file resale registration statement for Series G warrant shares by Jan 8, 2026, seek SEC effectiveness by Feb 9, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-037414","json":"https://secwatch.observer/filing/0001437749-25-037414.json","markdown":"https://secwatch.observer/filing/0001437749-25-037414.md","text":"https://secwatch.observer/filing/0001437749-25-037414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/mbrx20251210_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:38:44.816214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"578f77c43edf2cba738f481d4b4139495b721619","claim":"Moleculin Biotech, Inc. issued 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823 of warrant to holders of existing Series C warrants, Series D warrants and Series F warrants for aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants.","evidence_excerpt":"registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $6.63 per share, will be","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823"},{"label":"Purchaser","value":"holders of existing Series C warrants, Series D warrants and Series F warrants"},{"label":"Consideration","value":"aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants"}],"fact_type":"equity_issuance"},{"claim_id":"570661b5bc915de5a9981a9fae81ae40f7323450","claim":"Moleculin Biotech, Inc. entered into Inducement Letters with holders of existing Series C, Series D, and Series F warrants valued at up to approximately $6.8 million (effective 2025-12-09).","evidence_excerpt":"On December 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with: (i) the holder of existing Series C warrants and Series D warrants to purchase an aggregate of up to 727,969 shares of Company common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/0001437749-25-037414-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"holders of existing Series C, Series D, and Series F warrants"},{"label":"Value","value":"up to approximately $6.8 million"},{"label":"Effective","value":"2025-12-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}